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Diclofenac, a nonsteroidal anti-inﬂammatory drug, induces apoptosis on the neuroblastoma cell line SH-SY5Y through a
mitochondrial dysfunction, aﬀecting some antioxidant mechanisms. Indeed, the time- and dose-dependent increase of apoptosis
is associated to an early enhancement of the reactive oxygen species (ROS). Mitochondrial superoxide dismutase (SOD2) plays a
crucial role in the defence against ROS, thus protecting against several apoptotic stimuli. Diclofenac decreased the protein levels
and the enzymatic activity of SOD2, without any signiﬁcant impairment of the corresponding mRNA levels in the SH-SY5Y
extracts. When cells were incubated with an archaeal exogenous thioredoxin, an attenuation of the diclofenac-induced apoptosis
was observed, together with an increase of SOD2 protein levels. Furthermore, diclofenac impaired the mitochondrial membrane
potential, leading to a release of cytochrome c. These data suggest that mitochondria are involved in the diclofenac-induced
apoptosis of SH-SY5Y cells and point to a possible role of SOD2 in this process.
1.Introduction
Reactive oxygen species (ROS), normally produced during
the aerobic metabolism, function as second messengers
involved in many cellular functions. On the other hand,
when ROS level increases because of oxidant treatments
and/or defective antioxidant systems, these highly reactive
compounds and radicals become dangerous toxic agents.
In fact, ROS may cause severe damages to several cellular
macromolecules, including proteins, lipids, and DNA, thus
contributing to the development of many pathological
conditions. Indeed several evidences have been reported,
indicating that the redox homeostasis is a ﬁnely regulated
mechanism involved in normal cellular functions and pre-
vention of several stress-associated pathologies [1].
Many drugs have toxic side eﬀects, because they provoke
an imbalance of the intracellular ROS level. In the past,
cellular death due to a chemical injury was frequently
linked to a necrotic process; now, it is clear that the main
eﬀe c tp r o v o k e db ys e v e r a ld r u g si st h ep r o g r a m m e dc e l l
death[2].Diclofenac,anonsteroidalanti-inﬂammatorydrug
(NSAID) widely used in clinical therapeutics, has cytotoxic
eﬀects and induces apoptosis in many cultured cell lines
[3, 4]. This behaviour is common even to other NSAIDs
and some anticancer agents. Indeed, many experimental,
epidemiologic and clinical studies suggest that NSAIDs, and
in particular the highly selective cyclooxigenase-2 inhibitors,
could act as anticancer agents [5, 6]. It has been reported
that a combination of a speciﬁc NSAID and certain anti-
cancer drugs has potential clinical applications. For instance,2 Journal of Biomedicine and Biotechnology
diclofenac potentiates the chemotherapeutic eﬀects of some
drugs in neuroblastoma cell lines [7]. However, little is
known about the eﬀect of this NSAID on nervous cell lines
[8], because most of the studies on this compound regard
hepatic, gastric, or kidney cells [3, 4, 9]. In particular, ROS
are involved in the diclofenac-induced apoptosis of cultured
gastric cells as well as in nephrotoxicity in vivo [9, 10];
furthermore, an oxidative injury causes the mitochondrial
permeability transition in diclofenac-treated hepatocytes
[11]. However, the molecular mechanisms underlying the
induction of apoptosis by diclofenac have not been clariﬁed
in neuronal cells.
In this paper, we have investigated the involvement of
mitochondrial dysfunction in the mechanism of diclofenac-
induced apoptosis in the neuroblastoma cell line SH-SY5Y.
In particular, we have analyzed the role of the manganese
superoxide dismutase (SOD2) in this process. SOD2 is a
key enzyme of the mitochondrial matrix involved in the
protection against oxidative stress, which converts the toxic
superoxide anions to hydrogen peroxide and molecular
oxygen. Numerous reports have demonstrated that SOD2
hasanessentialroleintheprotectionagainstmanyapoptotic
stimuli [12–14]. In fact, in mice a partial deﬁciency of the
SOD2 gene (sod2(+/−)) increases the sensitivity to apoptosis
[15], whereas its overexpression has an antiapoptotic eﬀect.
In particular, SOD2 is involved in the inhibition of the
mitochondrial permeability transition after cell treatment
with tumor necrosis factor-α or ionizing radiations [16–
18], and blocks the Fas-mediated apoptosis [19, 20]. Our
data show that the treatment of the neuroblastoma cell
line SH-SY5Y with diclofenac induces a decrease in SOD2
protein level and an increase of the ROS concentration. This
impaired redox balance predisposes the cell to apoptosis
through a mechanism involving the mitochondrial pathway.
2.MaterialsandMethods
2.1. Chemicals. RPMI 1640 medium, fetal bovine serum
(FBS), L-glutamine, penicillin G, streptomycin and trypsin
were purchased from Cambrex. Diclofenac was obtained
from Calbiochem. Rhodamine 123 (R123), dichloroﬂuo-
rescein diacetate (DCFH-DA), and propidium iodide were
purchased from Sigma. A protease inhibitor cocktail was
obtained from Roche Diagnostics. Polyclonal antibody
against human SOD2 was purchased from Upstate; poly-
clonal antibody against GAPDH was obtained from Cell
signaling; polyclonal antibody against β-tubulin, goat poly-
clonal antibody against Cox-4, monoclonal antibody against
cytochrome c, and each secondary antibody conjugated
to horseradish peroxidase were obtained from Santa Cruz
Biotechnology.RecombinantthioredoxinA2fromthehyper-
thermophilic archaeon Sulfolobus solfataricus (SsTrx) was
obtained as previously reported [21]. All other chemicals
were of analytical grade and were purchased from Sigma.
2.2. Cell Culture. The human neuroblastoma cell line SH-
SY5Y was obtained from American Type Culture Collec-
tion. SH-SY5Y cells were grown in RPMI 1640 medium
supplemented with 10% FBS, 2mM L-glutamine, 100IU/ml
penicillin G, and 100μg/ml streptomycin, in humidiﬁed
incubator at 37◦C under 5% CO2 atmosphere. They were
split and seeded in plates (75cm2) every three days and used
for assays during exponential phase of growth.
2.3. Cytotoxicity Assay. An increasing concentration of
diclofenac was added to cultures, and cells were incubated
for diﬀerent times. Cytotoxicity was quantitatively assessed
by measurements of lactate dehydrogenase (LDH) activity
released in the extracellular ﬂuid from damaged or destroyed
cells [22]. Brieﬂy, diﬀerent aliquots of cell incubation media
were added to a 1-ml reaction mixture containing 0.1M
Tris-HCl, pH 7.5, 125μM NADH, and incubated for 15
minutes at 30◦C. The reaction started with the addition of
600μMsodiumpyruvateandwasfollowedbythedecreasein
absorbance at 340nm. The results were normalized to 100%
death caused by cell sonication.
2.4. Evaluation of Apoptosis. To determine the number of
apoptotic nuclei in diclofenac-treated cells, 3 ×104 cells/well
were seeded into 96-well plates; at the end of each treatment,
cell suspensions were centrifuged and pellets were resus-
pended in a hypotonic lysis solution containing 50μg/ml
propidium iodide. After incubation at 4◦Cf o r3 0m i n u t e s ,
cellswereanalysedbyﬂowcytometrytoevaluatethepresence
of nuclei with a DNA content lower than the diploid [23].
2.5. Detection of Intracellular ROS Content. The intracellular
ROS level was detected using the oxidation-sensitive ﬂuores-
cence probe DCFH-DA [11]. Brieﬂy, cells were seeded into
6-well plate (3 × 105 cells/well) and treated with 150μM
diclofenac for diﬀerent times. DCFH-DA was added in the
dark at 10μM ﬁnal concentration 30 minutes before the
end of each incubation; then cells were collected, washed in
10mMsodiumphosphate,pH7.2buﬀercontaining150mM
NaCl (PBS), and ﬁnally resuspended in 500μL of PBS for the
ﬂuorimetricanalysis.ThemeasurementoftheROSlevelswas
realised with a Cary Eclipse ﬂuorescence spectrophotometer
(Varian). Excitation and emission wavelengths were 485nm
and 530nm, respectively; both excitation and emission slits
were set at 10nm.
2.6.ReverseTranscriptasePolymeraseChainReaction. Forthe
analysisofSOD2mRNAexpression,totalRNAwasextracted
from 1 × 106 cells using a Trizol Reagent (Invitrogen)
as described by the manufacturer. The yield and integrity
of each RNA sample were checked spectrophotometrically
at 260nm and by agarose gel electrophoresis, respectively.
Equal amounts of RNA (2–4μg) were subjected to a
reverse transcriptase polymerase chain reaction (RT-PCR),
using a speciﬁc kit (Invitrogen) and random primers;
three dilutions of cDNA were ampliﬁed by PCR using Taq
D N Ap o l y m e r a s e( I n v i t r o g e n ) .F o rD N Aa m p l i ﬁ c a t i o no f
both SOD2 and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), the PCR program was 5 minutes initial denat-
uration at 95◦C, 20–23 cycles of ampliﬁcation (95◦C, 1
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step at 72◦C for 10 minutes. The following primers were
used: 5 d-TACGTGAACAACCTGAACGT-3  (sense) and
5 d-CAAGCCATGTATCTTTCAGTTA(antisense)forSOD2;
5 d-CACCATCTTCCAGGAGCGAG-3  (sense) and 5 d-
TCACGCCACAGTTTCCCGGA-3  (antisense) for GAPDH.
The ampliﬁed cDNA products were analysed by agarose gel
electrophoresis. SOD2 PCR products were normalized to the
respective intensity of the house-keeping gene GAPDH.
2.7. Evaluation of Mitochondrial Membrane Potential. Mito-
chondrial membrane potential was evaluated by measuring
the incorporation of the ﬂuorescent probe R123. Brieﬂy,
cells were seeded into 6-well plate (3 × 105 cells/well),
incubated at 37◦C for 1 hour in the presence of 5μM
R123, washed twice with PBS and placed in fresh complete
medium containing 150μM diclofenac. After diﬀerent times
ofdrugtreatment,themediumwaswithdrawn,andcollected
cells were washed twice with PBS. After detachment with
trypsin, cells were harvested in PBS and centrifuged at
4◦C for 10 minutes. Following aspiration of supernatant,
the cellular pellet was resuspended in 500μL of PBS.
The ﬂuorescence of cell-associated R123 was measured in
the above-mentioned ﬂuorescence spectrophotometer, using
excitation and emission wavelengths of 490nm and 520nm,
respectively; both excitation and emission slits were set at
10nm. The ﬂuorescence intensities were normalized versus
the cell number.
2.8. Total Cell Lysates and Western Blotting Analysis. SH-
S Y 5 Yc e l l sw e r ep l a t e da tad e n s i t yo f3× 105 cells/well
in 6-well plates, and 150μM diclofenac was added to the
cultures. After the drug treatment, cells were harvested,
washed with PBS, and then lysed in ice-cold modiﬁed
RIPA buﬀer (50mM Tris-HCl, pH 7.4, 150mM NaCl, 1%
Nonidet P-40, 0.25% sodium deoxycolate, 1mM Na3VO4,
and 1mM NaF), supplemented with protease inhibitors and
incubated for 30 minutes on ice. The supernatant obtained
after centrifugation at 12,000×gf o r3 0m i n u t e sa t4 ◦C
constituted the total protein extract. Protein concentration
was determined by the method of Bradford [24], using
BSA as standard. Western blotting analysis was realised on
equal amounts of each total protein extract. Brieﬂy, protein
samples were dissolved in SDS/reducing loading buﬀer, run
on a 14% SDS-PAGE, then transferred to Immobilon P
membrane (Millipore). The ﬁlter was incubated with the
speciﬁc primary antibody at 4◦C overnight and with the
horseradish peroxidase-linked secondary antibody at room
temperature for 1 hour. Membranes were then analyzed
by an enhanced chemiluminescence reaction, using Super
Signal West Pico kit (Pierce) according to the manufacturer’s
instructions; signals were visualized by autoradiography.
2.9. Subcellular Fractionation for Western Blotting Analysis
of Cytochrome c. SH-SY5Y cells were plated at a density of
2 × 106 cells/plate (75cm2). After treatment with 150μM
diclofenac, cells were harvested, washed in PBS, then
resuspended in buﬀe rM( 5 m MH e p e s ,p H7 . 4 ,2 5 0 m M
mannitol, 0.5mM EGTA, 0.1% BSA), supplemented with
protease inhibitors, and homogenized. The homogenate
was centrifuged at 800×gf o r1 0m i n u t e sa t4 ◦C, and
the supernatant was then centrifuged at 12,000×gf o r3 0
minutes at 4◦C. The resulting pellet (mitochondrial fraction)
was resuspended in buﬀer M and the ﬁnal supernatant
represented the cytosolic fraction. Protein concentration
was determined as previously indicated. Aliquots of both
fractions(cytosolicandmitochondrial)wereusedinWestern
blotting analysis for the cytochrome c localization.
2.10. Measurement of SOD Activity. SH-SY5Y cells were
plated at a density of 2 × 106 cells/plate (75cm2) and,
after one-day plating, 150μM diclofenac was added to the
cultures. Cells were then collected at diﬀerent times as pre-
viously indicated and then centrifuged at 300×ga t4 ◦Cf o r
5 minutes, washed once with PBS, and ﬁnally resuspended
in 50mM potassium phoshate, pH 7.8, containing 1mM
EDTA. The cellular suspension was sonicated, centrifuged
at 20,000×ga t4 ◦C for 30 minutes, and after protein
quantitation, the supernatant was used for an activity gel
a s s a y .I np a r t i c u l a r ,a l i q u o t so fc e l le x t r a c t s( 5 0 μg) were
fractionated on a 10% polyacrylamide gel and SOD activity
was evaluated as previously described [25]. This method is
based on the inhibitory eﬀect of SOD on the reduction of
nitro-bluetetrazoliumbythesuperoxideanionsgeneratedby
the photochemical reduction of riboﬂavin; SOD is visualized
as a colourless band over a blue background.
2.11. Statistical Analysis. All results are presented as his-
tograms and data are the average ± SD of at least three
independent measurements. In particular, data were ana-
lyzed by one-way ANOVA, and diﬀerences were considered
signiﬁcant when the corresponding P-values were <. 05 in
the Bonferroni’s post-hoc test.
3. Results
3.1. Diclofenac-Induced Apoptosis in the Human Neuroblas-
tomaCellLineSH-SY5Y. Toevaluatewhetherdiclofenachad
cytotoxic eﬀects on neuronal cells, the human neuroblas-
toma cell line SH-SY5Y was incubated for 24 hours with
increasing concentrations of diclofenac. Propidium iodide
incorporation followed by ﬂow cytometric analysis showed
a dose-dependent increase of apoptotic nuclei with sub-
diploid DNA content (Figure 1(a)). The cytosolic enzyme
lactate dehydrogenase (LDH) has been already used as a
marker of cytotoxic injury [11].Indeed,asigniﬁcantincrease
of LDH activity is typically found in culture media of cells
undergoing a disruption of plasma membrane. To this aim,
we have assayed the LDH activity in the culture media of
SH-SY5Y cells incubated up to 48 hours with increasing
concentrations of diclofenac. No signiﬁcant release of the
intracellular LDH was observed up to 150μM diclofenac
(not shown), which was taken as the maximal concentra-
tion of this compound not causing a signiﬁcant cytotoxic
eﬀect (MNTC). To analyse the time-dependent increase of
apoptosis, SH-SY5Y cells were exposed to 150μM diclofenac
and analysed at diﬀerent times. As shown in Figure 1(b), the4 Journal of Biomedicine and Biotechnology
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Figure 1: Diclofenac-induced apoptosis in SHSY-5Y cells. (a)
SH-SY5Y cells were incubated with the indicated concentrations
of diclofenac and apoptosis was evaluated after a 24-hour drug
treatment. (b) SH-SY5Y cells were treated with vehicle alone (white
bars)or150μMdiclofenac(blackbars)andapoptosiswasevaluated
after the indicated incubation times. The percentage of apoptosis
was measured as described in Section 2.4; ∗P<. 01 compared to
untreated cells.
apoptotic process was already evident after 8-hour treatment
and progressively increased up to 72 hours.
3.2. Eﬀect of Diclofenac on the Intracellular ROS Level. It is
known that NSAIDs alter the redox state of diﬀerent cell
types through an enhancement of intracellular ROS levels
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Figure 2: Eﬀect of diclofenac on the intracellular ROS level. SH-
SY5Ycellswereincubatedwithvehiclealone(whitebars)or150μM
diclofenac (black bars) for the indicated times. The intracellular
ROS level was evaluated through the usage of the ﬂuorescent probe
DCFH-DA, as described in Section 2.5. Fluorescence intensity was
reported as Arbitrary Units (AU); ∗P<. 01 compared to untreated
cells.
[9–11]. Therefore, we have decided to investigate whether
diclofenac aﬀects the intracellular ROS levels also in SH-
SY5Y cells, using the ﬂuorescent probe DCFH-DA. Indeed,
when these cells were incubated with diclofenac and DCFH-
DA at diﬀerent times, an early increase of the ROS level
was detected with respect to control cells; furthermore, ROS
production progressively continued at least up to 4 hours
(Figure 2).
3.3. Eﬀect of Diclofenac on SOD2 Levels. As SOD2 is the
primary antioxidant enzyme in mitochondria protecting
cells from oxidative injuries, we have evaluated the role
exerted by this enzyme in SH-SY5Y cells in the course
of diclofenac treatment. To this aim, the dose- and time-
dependent eﬀects of this drug on SOD2 protein levels of
SH-SY5Y cells were analysed in the experiments reported
in Figure 3. When these neuronal cells were incubated for
24 hours with increasing diclofenac concentrations, a dose-
dependent decrease of the SOD2 protein level was observed,
as evaluated by Western blotting using antibodies against
h u m a nS O D 2( Figure 3(a)). A similar picture emerged
when SH-SY5Y cells were incubated with 150μM diclofenac
a n da n a l y s e da td i ﬀerent times. The decrease of SOD2
levels (Figure 3(b)) was evident after 24-hour treatment and
increased at 48 hours.
To investigate the possibility that the reduction of the
SOD2 protein levels corresponded also to a decrease in SOD
activity, the protein extracts obtained from cells incubated
with150μMdiclofenacwereanalysedatdiﬀerenttimesusing
a SOD activity gel, which allows the detection of the activityJournal of Biomedicine and Biotechnology 5
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Figure 3:EﬀectofdiclofenaconSOD2proteinlevels.(a)Dosedependence.SH-SY5Ycellswereincubatedwiththeindicatedconcentrations
of diclofenac for 24 hours. The SOD2 protein level was evaluated by immunoblotting; as a loading control, the same ﬁlter was probed
with anti-GAPDH antibody. (b) Time dependence. SH-SY5Y cells were incubated with vehicle alone or 150μM diclofenac at the indicated
times and treated as indicated in (a). β-tubulin was used as house-keeping control. (c, d) Densitometry evaluation of three independent
experiments carried out as in (a) and (b), respectively; #P<. 05 compared to untreated cells.
of both mitochondrial SOD2 and cytosolic SOD1. Inter-
estingly, the SOD2 activity decreased in a time-dependent
manner (Figure 4), thus indicating that the reduction of the
enzyme level caused a lower eﬃciency in the defence against
the superoxide anions. Vice versa, the activity of SOD1 was
not aﬀected by the diclofenac treatment (not shown).
We also evaluated whether the diclofenac-induced
decrease of SOD2 levels/activity depends on a down-
regulation of the corresponding mRNA. To this aim, SH-
SY5Ycellswereincubatedinthepresenceorintheabsenceof
150μM diclofenac for 4, 8, and 24 hours. In order to evaluate
a possible regulation of the enzyme at transcriptional level,
after RNA extraction, a cDNA was obtained by reverse
transcriptase and used as a template in a PCR realised in
the presence of speciﬁc oligonucleotides for SOD2. The data
presented in Figure 5 indicate that the diclofenac treatment
did not signiﬁcantly alter the mRNA levels of SOD2 at
all times investigated. A similar picture with proportionally
lower signals emerged when dilutions of the cDNA template
were used in the RT-PCR assay (not shown). These results,
together with the low number of ampliﬁcation cycles used,
conﬁrm that the employed PCR conditions fell in the linear
dose-response range.
3.4. Eﬀect of a Heterologous Thioredoxin on the Antioxi-
dant Power of Diclofenac-Treated Cells. Thioredoxin (Trx),
a small (12kDa) and ubiquitous protein involved in many
cellular functions, is a potent disulphide oxidoreductase
controlling the reduced state of intracellular proteins. The
crucial antioxidant power of Trx also takes advantage of its
ability to cross the cellular membrane; in fact, evidences
have been reported that Trx can be released from cells
[26–28] and even enter a living cell [29, 30]. Moreover,
endogenously produced or exogenously added Trx increases
the SOD2 expression in lung carcinoma [31]o rn e u r o n a l
cells [32]. To this aim, the eﬀect of TrxA2 from the
hyperthermophilic archaeon Sulfolobus solfataricus (SsTrx)6 Journal of Biomedicine and Biotechnology
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Figure 4: Eﬀect of diclofenac on SOD2 activity. (a) SH-SY5Y
cells were treated with vehicle alone or 150μM diclofenac for
the indicated times. Total cell extracts were fractionated on a
nondenaturingpolyacrylamidegelandSOD2activitywasevaluated
as described in Section 2.10. (b) Densitometry evaluation of three
independent experiments; ∗P<. 01 compared to untreated cells.
on the reduction of SOD2 levels caused by diclofenac was
evaluated (Figure 6). When SH-SY5Y cells were treated with
150μM diclofenac, the SOD2 protein level was signiﬁcantly
reduced. The addition of increasing concentrations of SsTrx
allowed a restoration of the SOD2 level, thus counteracting
the eﬀect of diclofenac. In particular, in the presence
of 10μM SsTrx, the amount of SOD2 was even higher
compared to untreated cells. In a control experiment, the
addition of 10μM SsTrx did not cause any signiﬁcant
variation of the SOD2 level in the absence of diclofenac (not
shown).
T h ep o s s i b l ep r o t e c t i v ee ﬀect of SsTrx on the diclofenac-
induced apoptosis was also evaluated. As shown in Figure 7,
the addition of SsTrx partially reverted the programmed cell
death provoked by the drug. In particular, in the presence of
10μM SsTrx, the apoptosis of the diclofenac-treated cells was
reduced at all times investigated.
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Figure 5: Analysis of SOD2 mRNA level in SH-SY5Y cells treated
with diclofenac. (a) Total RNA extracts from SH-SY5Y cells,
incubated with vehicle alone or 150μM diclofenac for the indicated
times, were ampliﬁed by RT-PCR as indicated in Section 2.6 and
analysed on a 1% agarose gel. As a control, the ampliﬁcation of
GADPH from the same extracts was carried out. (b) Densitometry
evaluation of three independent experiments.
3.5. Eﬀect of Diclofenac on Mitochondrial Membrane Poten-
tial and Cytochrome c Localization. Loss of the membrane
mitochondrial potential occurs as an early event during the
apoptosisinducedbyspeciﬁcstimuliinsomecellularsystems
[33]. To better evaluate the molecular mechanisms under-
lying the diclofenac-induced apoptosis in SH-SY5Y cells,
the eﬃciency of the mitochondrial function was evaluated
through measurements of its membrane potential, using the
ﬂuorescent probe R123. It is known that this compound
crosses the mitochondrial membrane and accumulates into
the matrix, only when the transmembrane potential is
preserved; therefore, in case of a loss of the membrane
potential, the R123 ﬂuorescence undergoes a signiﬁcant
reduction [34]. As shown in Figure 8, the mitochondrial
incorporation of R123 in SH-SY5Y cells treated with 150μM
diclofenac underwent a signiﬁcant reduction compared toJournal of Biomedicine and Biotechnology 7
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Figure6:EﬀectofaheterologousthioredoxinonthereducedSOD2
proteinlevelcausedbydiclofenac.(a)SH-SY5Ycellswereincubated
for 24 hours in the absence or in the presence of 150μM diclofenac
plus the indicated concentrations of SsTrx. The SOD2 protein level
was evaluated by immunoblotting. As a loading control, the same
ﬁlterwasprobedwithananti-β-tubulinantibody.(b)Densitometry
evaluation of three independent experiments; #P<. 05 compared to
untreated cells; ∗P<. 01 compared to diclofenac-treated cells.
that measured on untreated cells. This hypopolarization of
the mitochondrial membrane caused by diclofenac became
evident after 2-hour treatment and signiﬁcantly increased
with the incubation time.
A deeper insight on the involvement of mitochondria
in the diclofenac-induced apoptosis was realised with a
Western blotting analysis aimed at the evaluation of the
cytochrome c release from mitochondria. In particular, the
detection of cytochrome c was carried out on both cytosolic
and mitochondrial protein fractions from SH-SY5Y cells
incubated in the absence or in the presence of 150μMo f
diclofenac at diﬀerent times (Figure 9). Interestingly, the
cytochrome c was already present after a 8-hour incubation
mainly in the cytosolic fraction of diclofenac-treated cells;
moreover, the amount of this mitochondrial marker in the
cytosol signiﬁcantly increased after a 24-hour treatment
(Figure 9(a)). This behaviour was conﬁrmed by the con-
comitant analysis on the mitochondrial fraction, where a
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Figure 7: Partial reversion of the diclofenac-induced apoptosis by
SsTrx. SH-SY5Y cells were incubated for the indicated times in
the absence (white bars) or in the presence of 150μM diclofenac
without (black bars) or with 10μM SsTrx (gray bars). The
percentage of apoptosis was measured as described in Section 2.4;
∗P<. 01 compared to untreated cells or diclofenac treated cells;
#P<. 05 compared to diclofenac-treated cells.
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Figure 8: Reduction of the mitochondrial membrane potential
in the presence of diclofenac. SH-SY5Y cells were incubated with
vehicle alone (white bars) or 150μM diclofenac (black bars)
for the indicated times. Mitochondrial membrane potential was
evaluated through the incorporation of the ﬂuorescent probe R123
as described in Section 2.7. ∗P<. 01 and #P<. 05, compared to
untreated cells.8 Journal of Biomedicine and Biotechnology
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Figure 9: Eﬀect of diclofenac on the subcellular distribution of cytochrome c. Cytosolic and mitochondrial fractions were prepared from
SH-SY5Y cells incubated in the absence or in the presence of 150μM diclofenac for the indicated times. Distribution of cytochrome c (Cyt
c) in cytosolic (a) and mitochondrial (b) fraction was evaluated by immunoblotting. The same ﬁlters were also probed with anti-GAPDH
(a) or anti-COX-4 (b) antibodies as loading control in the cytosolic or mitochondrial extracts, respectively. (c, d) Densitometry evaluation
of three independent experiments carried out as in (a) and (b), respectively; ∗P<. 01 and #P<. 05 compared to untreated cells.
reduction of the cytochrome c level was observed in the
diclofenac-treated cells (Figure 9(b)). These data indicate
that cytochrome c is released from the mitochondria, as a
consequence of the diclofenac treatment of SH-SY5Y cells.
4. Discussion
In this paper we describe the eﬀects of diclofenac on cultures
of the neuroblastoma cell line SH-SY5Y, thus extending to
this neuronal cell our knowledge on the possible toxicity of
this drug, already reported for gastric, hepatic, or renal cells.
Indeed, we present evidence that diclofenac induces apop-
tosis through a modulation of the mitochondrial function,
associated to an alteration of the redox homeostasis.
It is known that apoptosis is the primary cell death
induced by drugs [35] and that this process is mainly medi-
ated by the mitochondrial pathway [36, 37]. Here we show
that diclofenac induces apoptosis of SH-SY5Y cells in a time-
and concentration-dependent manner, thus suggesting that
this compound is somehow toxic even for a neuronal-type
cell.Previouspharmacokineticstudiesdemonstratedthatthe
blood level of diclofenac, on the basis of the therapeutic
doses used in patients (50–150 mg/day), ranges between
10 and 30μM[ 38]. However, in some circumstances the
local concentration of the drug might increase. In particular,
diclofenac concentration increases as a consequence of long-
term treatments, overdosing, limited clearance, and so forth,
as previously reported [39–42]. For these reasons, in our
in vitro studies we have used a diclofenac concentration of
150μM, because this value corresponded to the maximalJournal of Biomedicine and Biotechnology 9
concentration of this compound not causing cytotoxicity, as
determined by cytotoxicity assays on SH-SY5Y cells. In the
light of the large therapeutic usage of diclofenac, these data
are more relevant because of the known ability of this drug
to cross the blood-brain barrier [43]. Apoptosis is regulated
by many signals and metabolic events, and the cellular redox
state plays a critical role in this process. Indeed, several data
showed that ROS, mainly produced by mitochondria, are
involved in the programmed cell death through an induction
of the oxidative stress [44]. In particular, an increased ROS
level frequently represents a triggering event upstream of
the mitochondrial membrane depolarization, cytochrome c
release, caspase activation, and nuclear fragmentation [45].
An alteration of the ROS levels was already demonstrated
in diclofenac-induced apoptosis in gastric and renal cells
[9, 10]. Also in our neuronal cell system diclofenac provokes
an early and signiﬁcant increase of the intracellular ROS
levels.
These results prompted us to evaluate the downstream
eﬀects of altered ROS levels in the course of diclofenac
treatment of SH-SY5Y cells. Under this concern, SOD2
represents the major antioxidant enzyme in mitochondria,
where the intense cellular respiration may produce a large
amount of ROS. Therefore, an eﬃcient SOD2 activity
is required to counteract the mitochondrial dysfunction
induced by an oxidative stress, which could lead to the
programmed cell death usually observed in various disease
contexts [46]. The antiapoptotic role of SOD2 is even
demonstrated by the resistance to the radiation-induced
damage reported for cell lines overexpressing SOD2 [47].
Our data on SH-SY5Y cells show that diclofenac impairs
SOD2 functions, thus suggesting that this enzyme is involved
in the apoptotic mechanism induced by the drug. In
particular, this process is associated to a signiﬁcant and
concomitant reduction of both protein level and enzymatic
activity of SOD2, whereas RT-PCR experiments showed
that the corresponding mRNA levels are not aﬀected by
the diclofenac treatment. Therefore, a transcriptional regu-
lation of the SOD2 gene by diclofenac could be excluded;
probably, an increased degradation of the protein levels
could explain the reduced activity of the enzyme. The
behaviour of SOD2 in the diclofenac response was com-
pared with the eﬀects reported for other compounds in
various experimental systems. For instance, stautosporine,
a protein kinase inhibitor, did not aﬀect the mRNA levels
of SOD1 and SOD2, but decreased protein and activity
levels of both enzymes [48]. Other authors reported that
SOD2 is degraded by caspases in Jurkat T cells, following
oligomerization of the Fas receptor [20]. On the other
hand, in rat astrocytes the lipopolysaccharide induced an
increase of SOD2 mRNA, but not of the SOD2 protein [49].
These observations conﬁrm the regulation of SOD2 func-
tions following a drug treatment; however, the diﬀerences
observed among the various experimental systems indicate
that the SOD2 response is a multifactorial process only
poorly clariﬁed.
It is known that the induction of SOD2 can be mediated
by various macromolecules, such as interleukyn-1 [50],
lipopolysaccarides [51], and tumor necrosis factor-α [52];
furthermore, thiol-reducing agents can aﬀect SOD2 biosyn-
thesis, as demonstrated by the enhanced SOD2 expression
caused by thioredoxin, a potent disulﬁde oxidoreductase
[31]. In this paper, the addition of a heterologous thiore-
doxin to diclofenac-treated cultures of SH-SY5Y led to an
enhancement of the SOD2 levels, as well as to a reduction
of the apoptosis. This result conﬁrms the involvement of
SOD2 in the apoptotic processes induced by the drug
and suggests that an archaeal thioredoxin is active also in
human cells. Furthermore, we can speculate on a possible
functional interaction between heterologous components of
the thioredoxin system, because puriﬁed archaeal SsTrx was
added in its oxidised inactive form; its conversion to the
reduced active form involves a reaction putatively catalysed
by the human thioredoxin reductase.
The increased ROS level, the low functionality of the
mitochondrial antioxidant enzyme SOD2, together with
a partial recovery of SOD2 properties by a heterelogous
thioredoxin, strongly suggest the involvement of mitochon-
dria in the diclofenac-induced apoptosis of SH-SY5Y cells.
This hypothesis was conﬁrmed by measurements of the
mitochondrial membrane potential. Indeed, an excessive
p r o d u c t i o no fR O Sa n dad e c r e a s ei nS O D 2l e v e l sc o n t r i b u t e
to the mitochondrial dysfunction. In particular, after a
signiﬁcant loss of the mithocondrial membrane potential,
apoptosis-inducing factors are released from the mitochon-
dria, thus leading to the activation of the caspase cascade,
and ultimately to nuclear condensation [44, 45, 53, 54]. Also
in our system, the diclofenac treatment induces an early
mitochondrial hypopolarization, correlated to an increase of
the intracellular ROS levels, both events representing typical
features of the onset of mitochondrial apoptosis. Another
crucial marker of the intrinsic apoptosis is the cytocrome c
release from the mitochondria, as a consequence of mem-
brane depolarization. Our data showed that cytochrome c
translocates from the mitochondria to the cytosol during the
diclofenactreatmentofSH-SY5Ycells.Thisﬁnding,together
with the mitochondrial membrane depolarization, provides
a more direct link between mitochondria and diclofenac-
induced apoptosis, thus conﬁrming that the programmed
cell death in SH-SY5Y follows the mitochondrial path-
way.
The results obtained in this work could be relevant for
a deeper insight on the therapeutic usage of diclofenac,
pointing to the oxidative damage related to its cytotoxic
eﬀect. In particular, the involvement of the main antioxidant
mitochondrial enzyme in the apoptotic process may suggest
the use of SOD2 small interfering RNA in combination with
diclofenac, in order to improve the treatment of cancer, such
as neuroblastoma. On the other hand, diclofenac, because
of its ability to alter the cellular redox state of neuronal
cells, could be considered a neurotoxic compound. Under
this concern, previous studies showed that diclofenac and
indomethacin, another NSAID, enhance the eﬀects of some
neurotoxins on PC12 cells [55] and that diclofenac inhibits
the proliferation and diﬀerentiation of neuronal stem cells
[8]. Our results on the protective eﬀects of SsTrx open some
perspectives on the possible counteraction of the side eﬀects
caused by diclofenac.10 Journal of Biomedicine and Biotechnology
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